Skip to main content
. 2021 May 17;12:666067. doi: 10.3389/fpsyt.2021.666067

Table 1.

COVID-19 outcomes according to pre-existing schizophrenia.

References Article type Study population Prevalence of schizophrenia Outcome Risk
Fond et al. (13) Cohort study 50,750 1.60% In-hospital mortality 1.30 (1.08–1.56)*
Fond et al. (13) Cohort study 50,750 1.60% ICU admission 1.58 (1.09–2.3)*
Lee et al. (14) Cohort study 7,160 NA SARS-CoV-2 infection 1.00 (0.93–1.08)*
Lee et al. (14) Cohort Study 7160 NA Composite 2.27 (1.50–3.41)*
Wang et al (15). Retrospective 61,783,950 NA SARS-CoV-2 infection 7.34 (6.65 −8.10)*
Ji et al. (16) Retrospective 219,961 3.6% SARS-CoV-2 infection 1.6–1.7 (ORR)
Nemani et al. (17) Retrospective 7,348 1%** In-hospital mortality 2.67 (1.48–4.8)*
Taquet et al. (18) Retrospective 62,354 2% SARS-CoV-2 infection 1.17 (1.02–1.33)*

Composite, Death or ICU admission or invasive ventilation; ICU, Intensive care unit; NA, Not given;

*

Odds ratio (95% CI);

**

Schizophrenia spectrum disorder; ORR, Odds ratio range (95% CI not given).